香港股市 已收市

4D Molecular Therapeutics, Inc. (FDMT)

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。
加入追蹤清單
31.86-4.01 (-11.18%)
收市:04:00PM EDT
31.00 -0.86 (-2.70%)
收市後: 07:59PM EDT

4D Molecular Therapeutics, Inc.

5858 Horton Street
Suite 455
Emeryville, CA 94608
United States
510 505 2680
https://www.4dmoleculartherapeutics.com

版塊Healthcare
行業Biotechnology
全職員工147

高階主管

名稱頭銜支付行使價出生年份
Dr. John F. Milligan Ph.D.Executive Chairman150k1961
Dr. David H. Kirn M.D.Co-Founder, CEO & Director920.97k1962
Dr. Fariborz Kamal Ph.D.President & COO678.4k1963
Dr. Noriyuki Kasahara M.D., Ph.D.Chief Scientific Officer13.6k1963
Ms. Theresa JankeCo-Founder & Chief of Staff652.32k1975
Mr. Uneek MehraChief Financial & Business Officer1972
Dr. Scott P. Bizily J.D., Ph.D.Chief Legal Officer & Corporate Secretary1973
Dr. Robert Y. Kim M.B.A., M.D.Chief Medical Officer1961
Dr. An Song Ph.D.Chief Development Officer
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.Senior VP & Therapeutic Area Head of Pulmonology1961
截止 2022年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

公司管治

截至 2024年3月1日 止,4D Molecular Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:2;董事會:6;股東權利:8;現金賠償:9。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。